BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
← catalyst calendarNCT05456880 · readout ≤ 559 d
Sponsored by Beam Therapeutics Inc. (industry) · BEAM — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
15estimated
Sites
19
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-30 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Intervention
- Biological: BEAM-101
Primary outcomes
what the primary-completion date above is the date OFChange in annualized number of severe VOCs (Vascular-occlusive Crisis) relative to baseline
measured 6 months to time of analysis as compared to baseline
Proportion of patients with successful neutrophil engraftment
measured BEAM-101 administration to month 24
Time to neutrophil engraftment
measured BEAM-101 administration to month 24
Time to platelet engraftment
measured BEAM-101 administration to month 24
Transplant-related mortality within 100 days after beam-101 treatment
measured BEAM-101 administration to day 100
Safety and tolerability assessments based on frequency, severity and seriousness of adverse events (AE's)
measured BEAM-101 administration through month 24
Publications
- PMID 41931046 — linked by the registry
- PMID 38866240 — linked by the registry
- PMID 36975201 — linked by the registry
- PMID 36860093 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BEAM's whole pipeline · Catalyst calendar · Every registered study · What changed